analysis demonstrates an association between the uremic state and lower Tregs, and supports the hypothesis that hemodialysis alter Tregs. Our findings highlight the need for new clinical studies. Video Journal Club 'Cappuccino with Claudio Ronco' at
Introduction
One of the major challenges of the immune system is to preserve immune tolerance to self while maintaining the ability to fight foreign pathogens and infectious agents [1] .
Different research groups have demonstrated that patients with chronic kidney disease (CKD) stages G5 not on dialysis (CKD G5), CKD GFR stages G5 on dialysis patients (CKD G5D) or patients with acute kidney injury [2] suffer from immune system dysregulation characterized by immune incompetence as well as signs of chronic inflammation [3] . The condition of uremia per se is characterized by a series of metabolic disturbances that produce an imbalance between immunostimulation and immunosuppression [4] .
The state of inflammation has been associated with malnutrition, anemia, an increased risk of cardiovascular disease and higher mortality rates [5] .
An additional explanation for this state of immune dysregulation may be the reduced number or impaired function of regulatory T-cells (Treg) [6] . Treg cells are a subset of CD4 T-cells that highly express CD25 and FoxP3 with low or absent expression of CD127 [7] . In addition to their widely known function to inhibit the activation of CD4 and CD8 T-cells and antigen presenting cells, Treg cells also inhibit innate immune cells such as monocytes/macrophages and neutrophils [8] [9] [10] [11] .
Treg cells constitute a natural defense mechanism against inflammation and thus their modulation may be a key determinant of the immune status in CKD patients. Moreover, modulation of Treg numbers up or down leads to resistance or increased susceptibility to kidney injury, respectively [12] .
Treg Cells and End-Stage Renal Disease
CKD progresses to end-stage renal disease (define as GFR stage G5: estimated GFR <15 ml/min/1.73 m 2 ) at a variable rate. Nearly half of CKD G5D patients suffer from chronic inflammation, which is caused by several factors including uremic toxins, issues of biocompatibility to dialysis membranes and other etiologies [13, 14] . Paradoxically, in the setting of chronic immune cell activation, CKD G5D patients are at increased risk for several types of infections and respond poorly to vaccinations [15, 16] .
This meta-analysis focuses on the involvement of Treg cells in the immune regulation of CKD G5D patients (definition accorded to reference [17] ) and defines the current data set on the influence of dialysis on this type of cell to better target key research questions in this evolving area.
The aim of this study is to determine whether the available literature supports a positive or negative influence of dialysis on Tregs.
Methods
The meta-analysis was conducted according to the checklist of the Meta-Analysis of Observational Studies in Epidemiology group [18] . We performed a systematic search of relevant studies published through May 2015 in the Medline database.
Literature Search
Eligible studies up to May 2015 were identified by searching the Medline 1950 (US National Library of Medicine, Bethesda, Md., USA) database using PubMed software as the search interface, and the ISI Science Citation Index using the ISI Web of Science search interface, and by hand-searching the reference lists of the retrieved articles.
For computer searches, we used the following medical subject headings, terms or text words: T lymphocytes regulatory, Treg, CD4+CD25+, FoxP3 and dialysis.
We read the abstracts of all identified studies to exclude those that were clearly not relevant. The full texts of the remaining articles were read to determine if they met study inclusion criteria.
Inclusion and Exclusion Criteria
Cohort studies including population-based record linkage studies that assessed the relationship between Treg cell number and dialysis treatments were included.
Any discrepancies between investigators about inclusion of a study were resolved by joint evaluation of the manuscript.
Data Extraction
Two researchers independently abstracted data from identified studies using a standardized data abstraction form, with inconsistencies resolved by consensus. The reviewers extracted data about characteristics of participants, clinical setting, number of Treg cells, percentage of Treg cells out of CD4+ in CKD G5 patients, healthy controls (HCs) and CKD G5D patients.
Studies were eligible for inclusion based upon the following criteria: (1) Studies published after 2009. Before this date, human Treg cell markers were not well characterized and the FACS gating strategies were not uniform, so not comparable. (2) All types of articles except reviews. (3) Studies that performed FACS analysis with the following antibodies: (1) CD4+, (2) CD25 bright (instead of just CD25+), (3) CD127-and/or (4) FoxP3+. If only CD25+ was used instead of CD25 bright then this must have been combined with either CD127 negativity or FoxP3 positivity for inclusion in our study. There was no language restriction. Each article chosen by the primary reviewer was reviewed by a second reviewer to confirm eligibility.
Animal studies or studies that did not include a control population were excluded.
A tabular summary of the relevant studies is provided ( table 1 ) [6, 13, 15, [19] [20] [21] [22] [23] [24] [25] .
Data Synthesis and Analysis
Three different groups of patients were compared. CKD G5D patients were compared to HCs; CKD G5 patients were compared to HC and with CKD G5D in terms of mean differences in the number of Treg cells. The means and SDs of number of Treg cells were extracted from individual studies, and the pooled variance for the mean differences was calculated for each study. According to the p values <0.1 of the heterogeneity test, random effects model was performed. For each meta-analysis, we assessed the between-study heterogeneity using the tau-square statistic and study consistency using the I-square statistic. p value of <0.05 was judged as statistically significant. All statistical analyses were performed using the general package for meta-analysis (version 4.3-0, depends R ( ≥ 2.9.1)).
Results

Study Characteristics and Selection
Our electronic searches identified 83 articles, of which 19 were considered potentially relevant and were selected for full text review ( fig. 1 ). Nine observational studies were considered eligible but were excluded for the following reasons: 4 did not include a control group other than CKD G5D patients, 3 did not use the pre-defined Treg cell identification criteria, 1 is a review and 1 is not a human study.
Ten studies fulfilled the inclusion criteria and are part of the systematic review; 5 articles are excluded from the meta-analysis: 4 articles do not report numerical data that are only described and discussed, making impossible their inclusion in the statistical analysis [6, 19, 20] and 1 manuscript had imprecision in the materials and methods section such that it is not possible to understand how they count Treg cells [26] . Five studies that included comparable HC and CKD G5D patients and used similar criteria for determining the percentage of Treg cells in total CD4 T-cells were subjected to a meta-analysis [13, [21] [22] [23] [24] . The complete list of articles included in the systematic review is described in table 1 . A total of 99 CKD G5D patients, 88 HCs and 57 CKD G5 patients were included in our meta-analysis. There was a 100% concordance between reviewers with respect to final inclusion and exclusion of studies reviewed based on the predefined inclusion and exclusion criteria.
Patient Characteristics
Salient demographic characteristics of participants enrolled in the included clinical trials are shown in table 1 . The mean age of patient cohorts ranged from 35.7 to 60.4 years in the HC group and from 46.3 to 58.6 years in the CKD G5D patients group. The sex distribution ranged from 30 to 87% male. The mean duration of dialysis in CKD G5D patients group is from more than 6 to 56.3 months.
Treg Cells in CKD G5D Patients versus HC
In 5 out of 10 studies, the mean percentage of Treg cells/CD4+ was reported. These studies are included in the meta-analysis ( table 1 ) .
A total of 99 CKD G5D patients and 88 age-matched HCs were included from these 5 studies. Using the random effects model, there was a trend toward a decrease in percentage of Treg cells in CKD G5D patients that did not reach statistical significance ( fig. 2 ) .
Treg Cells in CKD G5 versus HC and CKD G5D versus CKD G5
We performed 2 additional meta-analyses between CKD G5 patients versus HCs ( fig. 3 ) and CKD G5 versus CKD G5D patients ( fig. 4 ) . The studies included in this additional analysis are Lisowska et al. [13] , Kim et al. [22] and Zhang et al. [23] . This analysis aimed to understand if the difference measured between CKD G5D patients and HCs is due to uremic state or hemodialysis treatments.
A total of 57 CKD G5 patients and 67 age-matched HCs were included in the 3 studies used in this analysis. Using the random effects model, a significant difference in the percentage of Treg cells in total CD4 T-cells between CKD G5 and HCs was observed (p = 0.002). The mean difference in Treg percentage was -2.47% in CKD G5 patients versus HCs ( fig. 3 ) .
A total of 78 CKD G5D patients and 57 CKD G5 patients were included in a separate analysis. Using the random effects model, there was a trend toward a decrease in percentage of Treg cells in CKD G5D patients that did not reach statistical significance ( fig. 4 ) .
Discussion
The question remained as to why pro-inflammatory mediators and monocyte activation do not protect CKD G5D patients from infections and on the contrary, why these patients are more infection-prone than normal subjects. A possible explanation is a clinical condition with a progressive and mild systemic inflammatory response syndrome (SIRS) with a chronic imbalance between humoral and cellular mechanisms that counteract or promote the development of SIRS itself [27] . Compensatory anti-inflammatory response syndrome and SIRS can coexist in patients on dialysis with competing influences of inflammation and immune depression [2] . The immune system of CKD G5D patients is affected by many factors; as a result, there is activation of different T-cell subsets.
The consequence of premature activation of T-cells is impaired proliferative capacity and decreased cytokine production. A recent study reported the absence of Treg cell mobilization despite the presence of T-cell activation in these patients. Thus, it appears that hemodialysis not only The meta-analysis demonstrated that in the studies published on this subject Treg/CD4+ proportion is lower in the CKD G5 patient group than in HC ( fig. 3 ) .
Our hypothesis was that not only the uremic state but also hemodialysis treatments would influence Treg/ CD4+ percentage and Treg cell number. To investigate the effect of hemodialysis treatment on the Treg/CD4+ proportion, we performed a further statistical analysis between CKD G5 versus HC and CKD G5D versus CKD G5.
The results of this further analysis show that there is no statistical difference between CKD G5 and CKD G5D groups suggesting that the uremic state is the principle cause of lower Treg/CD4+ percentage. Yoon et al. [28] demonstrated that the reduction in the numbers of naïve and central memory T-cells in uremic patients may be due to heightened susceptibility of these cells to apoptosis.
In the current study, when the CKD G5D group is included, the difference is not statistically significant and this could be due to the effect of hemodialysis on CD4+ T-cells. Lowering of non-Treg CD4+ T-cells [14] would tend to maintain the fraction Treg/CD4+ unchanged and hide reductions in Treg cell numbers. This idea is supported by all other articles included in the systematic review that analyze Treg absolute number, adding strong support to the hypothesis that hemodialysis treatments are responsible for lowering not only CD4+ T-cells in general, but also Treg cells [6] . With one exception (Chen et al. [26] ), Treg are thought to be lower in CKD G5D subjects. Hendrikx et al. [6] , Baron et al. [19] and Topal et al. [20] evaluated absolute number of Treg (in CKD G5D subjects) and have showed that Treg absolute number is lower in these patients in comparison to HC. These results are similar to our current meta-analysis and do not show a difference in Treg/CD4+ percentage. This could be due to small differences in cell number (Treg and CD4+) and the lower number of patients, or it could be that the percentage of Tregs/CD4+ does not change with dialysis, but the total number of both Tregs and total CD4+ T-cells is reduced by dialysis. The paper of Chen et al. [26] showing a dramatic increase in the frequency of Tregs in CKD G5D patients in comparison to HCs deserves a special comment. In the study, the frequency of Treg cells reported in CKD G5D patients (5.92 and 4.46%) are in the expected range, while they show very small frequency of Treg in HCs; so it appears from their manuscript that there is an approximately 15-fold increase in the frequency of Treg cells in CKD G5D patients that seems highly unlikely given the much lower magnitude of changes reported in each of the other studies.
Afzali et al. [21] showed that although FoxP3 expression was similar in freshly isolated Tregs from CKD G5D subjects and controls, impaired Treg-mediated suppression of autologous T responding cells was seen in hemodialysis patients. Because this finding was apparent in the absence of uremic serum, they concluded that the majority of the functional defect is cell-intrinsic (i.e., the Tregs are defective) rather than cell-extrinsic (uremic toxins, oxidized low-density lipoprotein and hypercytokinemia) [21] . On the other hand, Candida bloodstream infections is one cause of morbidity and mortality in hemodialysis patients [29] and mouse studies have demonstrated that Tregs are required for effective clearance of Candida albicans infections [30] . Thus, effective Treg numbers and functional capacity are important for limiting excess inflammation and properly eradicating some types of infections.
Our impression is that CD4+ T-cells become more activated with CKD G5D, but their numbers decrease and, at the same time, Treg cell numbers and suppressive function are reduced so they are not able to effectively restrain activated CD4+ T-cells and possibly other pro-inflammatory leukocytes.
Limitations of our meta-analysis include relatively small number of studies to use for comparison and some slightly different criteria for identifying Tregs in the studies used for meta-analysis (CD4+CD25high vs. CD4+FoxP3+ vs. CD4+CD127lowCD25high). We were also limited by the lack of information reported by each study on important parameters such as length of time on dialysis, type of dialysis, moment of blood sampling (before or after the dialysis treatment) and length of CKD. Most studies did not include this information and these variables can confound the results. This highlights the need for standardized methods of enrollment of patients, sampling and analysis of Treg cells.
This meta-analysis and systematic review support the hypothesis that hemodialysis is associated with changes in Tregs overall. Moreover, it demonstrated a clear impact of uremia on Treg cells number as supported by the analysis between CKD G5 patients and HCs. However, our findings and the limitations listed above emphasize the need for new clinical studies and more detailed methods by authors who are conducting studies on this subject. To answer the question of whether 'dialysis influences Treg cells', it is necessary to perform a prospec-tive clinical study sampling Treg cells at different time points from the same patient, before and then different times after initiation of dialysis. This could lead to an improved understanding of Treg cell function and the influence of dialysis treatments on these cells and other immune cells. Furthermore, linking the changes in Treg number and function to outcomes in dialysis patients is an important next step in this area of study.
